Why Jefferson Institute for Bioprocessing Has Become a Preeminent Model for Biomanufacturing Workforce Training 

Published on :

The Jefferson Institute for Bioprocessing (JIB) is a jewel in the crown of Cellicon Valley. The institute provides critical training in biomanufacturing and bioprocessing for next-generation biologics, vaccines, and cell and gene therapies; skills that are in urgent demand by employers everywhere who are being challenged to find enough experienced employees to sustain their growth.

Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth

Published on :

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the appointment of three new executive leaders including Scott Greenberg as Chief Operating Officer, Jeffrey Staiger as Senior Vice President of Finance and Business Development, and Michael Tortorici, PharmD, Ph.D. as Vice President of Clinical Pharmacology and Non-Clinical Development. Mr. Greenberg most recently served as Chief Business Officer of Aro, while Mr. Staiger and Dr. Tortorici are new additions to the leadership team. The Company also announced plans to move its headquarters to The Curtis in Philadelphia to accommodate ongoing growth of its operations and staff.

LucasPye and IndyGeneUS AI Forge Partnership To Address Drug Development and the African Diaspora

Published on :

Over the years, minority input in the clinical development of life-saving drugs has been lacking, particularly when it comes to clinical trial participation. That has led to disparities in the efficacy of medications when taken by minority

Industry Experts Weigh in on Why Philadelphia’s Life Science Real Estate Market is Booming

Published on :

Philadelphia’s soaring life sciences commercial real estate market is being driven by the combination of strong demand for advanced lab and manufacturing facilities and near record low vacancy rates.

Gyroscope’s “Vision for Life” Eyes $100M+ IPO

Published on :

Gyroscope Therapeutics, a gene therapy company developing treatments for eye diseases, filed a Form F-1 with the U.S. Securities and Exchange Commission announcing its intention to begin selling American Depository Shares on the Nasdaq Exchange under the ticker symbol “VISN.” At the time of its filing this week, Gyroscope said it has not yet set the pricing terms for its stock. The $100 million is a placeholder figure. Based on positive clinical activity, and a recent financing round, the company is likely to raise significantly more than $100 million.